tat

TAT peptide (YGRKKRRQRRR), originating from the human immunodeficiency virus-1 (HIV-1) transactivator of transcription (TAT), enhances the solubility and production of heterologous proteins[1]. This cell-penetrating peptide demonstrates significant potential in biotechnological applications.

Tat-NR2B9c acetate (NA-1 acetate) is a postsynaptic density-95 (PSD-95) inhibitor, with EC50 values of 6.7 nM and 670 nM for PSD-95d2 (PSD-95 PDZ domain 2) and PSD-95d1, respectively. Tat-NR2B9c acetate disrupts the PSD-95 NMDAR interaction, inhibiting NR2A and NR2B binding to PSD-95 with IC50 values of 0.5 μM and 8 μM, respectively. Tat-NR2B9c acetate also inhibits neuronal nitric oxide synthase (nNOS) PSD-95 interaction, and possesses neuroprotective efficacy.

TAT-GluA2 3Y acetate is an inhibitor of AMPA receptor endocytosis.Systemic administration of Tat-GluA2(3Y) during the induction phase of d-amphetamine blocked maintenance of behavioural sensitization and attenuated the maintenance of neurochemical sensitization of rat.

TAT-Gap19 acetate is a specific inhibitor of connexin43 hemichannel (Cx43 HC). TAT-Gap19 acetate traverses the blood-brain barrier and alleviates liver fibrosis in mice. TAT-Gap19 acetate does not inhibit the corresponding Cx43 GJCs.

Biotin-TAT (47-57) acetate is a biotin-labeled TAT polypeptide and a transactivator of transcription. Biotin-TAT (47-57) acetate is one of the most widely used peptides in protein transduction domains.

(Cys47)-HIV-1 tat Protein (47-57) possesses membrane translocation functionality and can serve as a surface derivatization agent for magnetic pharmaceuticals, enhancing their uptake into specific target cells.

Biotin-TAT (47-57) is a biotin-tagged transactivator of transcription, commonly employed as a protein transduction domain (PTD) in various primary cells. Its transduction capacity is contingent on ATP and temperature, suggesting the participation of endocytosis.

Cys-TAT(47-57) (Cys-[HIV-Tat (47-57)]) is an arginine-rich cell-penetrating peptide derived from the HIV-1 transactivating protein, corresponding to the protein transduction domain of the TAT protein.

Tat-beclin 1 acetate is a potent inducer of autophagy and interacts with the negative regulator of autophagy, GAPR-1. Tat-beclin 1 acetate decreases the accumulation of polyglutamine expansion protein aggregates and the replication of several pathogens (including HIV-1).

Tat-Gap 19, a peptide inhibitor of connexin43 (Cx43) hemichannels, is derived from the HIV-1 Tat protein transduction domain fused with a nine-amino acid sequence from Cx43 residues 128-136. This compound, at a concentration of 10 µM, effectively suppresses glutamate-induced ATP release in primary rat hepatocytes, indicating inhibition of Cx43 hemichannel activity. Furthermore, Tat-Gap 19 demonstrates therapeutic potential by significantly reducing infarct volume in a mouse cerebral ischemia-reperfusion injury model following middle cerebral artery occlusion (MCAO) at a dosage of 25 mg/kg. Moreover, its intraperitoneal administration at 1 mg/kg per day ameliorates fibrosis and decreases the area of hepatic stellate cells, the precursors to myofibroblasts, expressing α-smooth muscle actin (α-SMA), in a model of thioacetamide-induced liver damage. Additionally, it enhances superoxide dismutase (SOD) activity in hepatic cells from the treated mice, indicating its antioxidative benefits.

Cx43 hemichannel blocker (IC50 ~7 μM). No significant affinity for gap junctions or Panx1 channels. N-terminal transactivator of transcription (TAT) motif promotes membrane permeability and increases inhibitory effect of Gap19. Active in vivo. Brain penet

TAT-DEF-Elk-1 acetate is a cell-penetrating peptide inhibitor of ERK1 2 kinase phosphorylated Elk-1 with antitumor and antidepressant activity.TAT-DEF-Elk-1 acetate inhibits the phosphorylation of Elk-1, inhibits Elk-1 nuclear TAT-DEF-Elk-1 acetate inhibits Elk-1 phosphorylation and Elk-1 nuclear translocation, and can be used to study depression.

TAT-CIRP, a trans-activating (Tat) cold-inducible RNA-binding protein-derived peptide, functions as an inhibitor of myeloid differentiation protein 2 (MD2). It has demonstrated significant neuroprotective effects against ischemic and hemorrhagic stroke in mouse models [1].

FITC-LC-TAT (47-57), a fluorescein isothiocyanate (FITC)-labeled trans-activator of transcription (TAT) peptide, is recognized as a cell-penetrating peptide (CPP) and enhances the yield and solubility of heterologous proteins [1].

TAT-GluR23A Fusion Peptide is a bioactive peptide comprising the GluR23A sequence—residues 869 to 877 of GluR23Y with alanine replacing tyrosine—and an 11 amino acid cell-permeable HIV Trans-Activator of Transcription (TAT) protein transduction domain (PTD). It serves as an inactive control counterpart to the glutamate receptor endocytosis inhibitor GluR23Y, devoid of crucial phosphorylation sites.

TAT-NSF700scr comprises the complete TAT domain and a glycine linker, succeeded by the NSF amino acids arranged randomly. It serves as a control peptide, ineffective in inhibiting SNARE-mediated exocytosis [1] [2].

Tat-beclin 1 TFA, a peptide derived from a segment of the autophagy protein beclin 1, effectively induces autophagy and interacts with the autophagy negative regulator GAPR-1 (GLIPR2). It reduces the accumulation of polyglutamine expansion protein aggregates and limits the in vitro replication of various pathogens, including HIV-1. Additionally, Tat-beclin 1 TFA has been shown to decrease mortality rates in mice infected with chikungunya (CHIKV) or West Nile virus (WNV) [1].

Myr-TAT-CBD3, a CRMP2-CaV2.2 interaction inhibitor, has been shown to significantly attenuate carrageenan-induced thermal hypersensitivity and reverse thermal hypersensitivity in a rat model of postoperative pain, making it a useful compound for studying inflammation and postoperative pain [1].

Cys-TAT(47-57) acetate is derived from the HIV-1 transactivating protein. Cys-TAT(47-57) acetate is an arginine rich peptide that can penetrate cells.

TAT-N24 is a cell-penetrating TAT peptide that functions as a p55PIK signaling inhibitor. By suppressing the HIF-1α NF-κB signaling pathway in corneal sutures (CS), TAT-N24 can treat corneal neovascularization (CNV) and ocular inflammation. Additionally, TAT-N24 inhibits the formation of corneal neovascularization.

TAT-amide TFA is a cell penetrating peptide. The cell - penetrating peptides (CPPs) is a kind of access to the short amino acid sequence of different cells.

TAT (48-57) (TFA) is a cellular permeability peptide derived from hiv-1 transcriptional activator (TAT) protein residue 48-57.

TAT (48-57) acetate is a cell-permeable peptide derived from the HIV-1 transactivator of transcription (Tat) protein, encompassing amino acid residues 48 to 57 from the basic domain of HIV Tat.

Tat-CIRP, a peptide inhibitor, impedes the protein-protein interaction between myeloid differentiation 2 (MD-2), also known as lymphocyte antigen 96 (LY96), and cold-inducible RNA binding protein (CIRP) by binding to MD-2. This disrupts the MD-2 and CIRP interaction as confirmed in co-immunoprecipitation assays. Notably, in vivo studies reveal that Tat-CIRP, at dosages of 10 and 20 mg/kg, significantly reduces infarct volume in both a mouse model of middle cerebral artery occlusion (MCAO) and a rhesus monkey model of thrombosis-induced stroke. Additionally, it improves motor function, evidenced by decreased time to manipulate and withdraw food with the affected arm in the primate model.